Stocktoria
Cingulate Inc. CING
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-10-07
Cingulate Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $9.8M | $9.4M | $15.5M | $9.0M | $8.4M |
| Operating income | -$19.9M | -$15.6M | -$22.8M | -$17.5M | -$20.7M |
| Interest expense | — | — | $790,000 | $292,339 | — |
| Net income | -$22.4M | -$16.6M | -$23.5M | -$17.7M | -$20.7M |
| EPS (diluted) | $-4.44 | $-10.86 | $-311.99 | $-29.35 | — |
| Operating cash flow | -$17.2M | -$18.5M | -$15.0M | -$15.9M | -$10.4M |
| Free cash flow | -$17.4M | -$18.7M | -$15.3M | -$16.0M | -$11.2M |
| Cash & equivalents | $11.0M | $12.2M | $52,416 | $5.4M | $16.5M |
| Total assets | $15.1M | $14.9M | $3.5M | $11.4M | $22.9M |
| Total liabilities | $12.6M | $7.4M | $10.4M | $7.5M | $2.0M |
| Shareholders' equity | $2.5M | $7.5M | -$6.9M | $3.9M | $20.8M |
Source: SEC EDGAR filings · CIK 0001862150 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.